ArticleBlood2014
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis.Journal of cancer research and clinical oncology · 2015Pooled it
- A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.Leukemia · 2024Trial
- Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.Bone marrow transplantation · 2019Trial
- Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Trial
- Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group.Bone marrow transplantation · 2026Article
- The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations.Transplantation and cellular therapy · 2026Article
- Article
- Review
- TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation.Blood advances · 2025Article
- Prognostic factors for survival after allogeneic transplantation in acute myeloid leukemia in Iran using censored quantile regression model.Scientific reports · 2025Article
- Rapid Detection ofBiomolecules · 2024Article
- Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML.Blood advances · 2024Review
- The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.Frontiers in immunology · 2024Review
- Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.International journal of hematology · 2023Review
- A novel mesenchymal stem cell-based regimen for acute myeloid leukemia differentiation therapy.Acta pharmaceutica Sinica. B · 2023Article
- Article
- Transplant for TP53-mutated MDS and AML: because we can or because we should?Hematology. American Society of Hematology. Education Program · 2022Article
- Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.Transplantation and cellular therapy · 2021Review
- Article
Corrections and comments
- Commented on by
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with acute myeloid leukemia (AML) and abnormalities of chromosome 17p (abnl(17p)) are at high-risk of treatment failure. Poor outcomes have been reported with conventional chemotherapy. To accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with abnl(17p) AML, we analyzed the results of patients with this abnormality who received an allogeneic HSCT between January 2000 and December 2010 in 1 of 4 well-defined cohorts (Fred Hutchinson Cancer Research Center, Haemato Oncology Foundation for Adults in the Netherlands, Study Alliance Leukemia, German Cooperative Transplant Study Group). Data of 201 patients with a median age of 54 years were evaluable. At the time of analysis, 30 patients were alive with a median follow-up of 30 months. The 3-year probability of overall survival (OS) was 15% (95% confidence interval [CI], 10-20). The cumulative incidence of relapse at 3 years was 49% (95% CI, 42-56). Notably, almost 70% of all relapses occurred within the first 6 months after HSCT. Patients who were transplanted in first complete remission (CR1) had superior OS compared with those with advanced disease (22% vs 9%, P < .001). Our findings confirm the high-risk of treatment failure in abnl(17p) AML even after allogeneic HSCT in CR1. Although allogeneic HSCT remains a valid option in CR1, alternative treatment strategies are needed for the remaining patients.
Indexed as
Identifiers
24652988What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.